ArticleJournal of neurology, neurosurgery, and psychiatry2020
Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis.
Article in Journal of neurology, neurosurgery, and psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 111 citations in OpenAlex.
- A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Trial
- The influence of anti-CD20-directed B cell depletion across different agents on Epstein-Barr virus-specific humoral and cellular immunity in patients with multiple sclerosis.Journal of neuroinflammation · 2026Article
- Article
- Epstein-Barr Virus and Multiple Sclerosis: Mechanistic Insights into Virus-Driven Autoimmunity.Microorganisms · 2026Review
- EBV genome analysis in multiple sclerosis shows extensive viral diversity and links to autoimmunity.NAR molecular medicine · 2026Article
- Epstein-barr virus and multiple sclerosis: from pathogenesis and diagnosis to EBV-specific T cell therapy and gene-targeted therapeutics.Journal of applied genetics · 2026Review
- Genome-wide discovery of multiple sclerosis genetic risk variant allelic regulatory activity.G3 (Bethesda, Md.) · 2025Article
- Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein-Barr Virus and Multiple Sclerosis.European journal of neurology · 2025Article
- Epstein-Barr Virus in Multiple Sclerosis: Past, Present, and Future.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.Journal of neurology · 2025Article
- Epstein-Barr Virus Seropositivity, Immune Dysregulation, and Mortality in Pediatric Sepsis.JAMA network open · 2025Article
- Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1Nature communications · 2025Article
- Causal association between EBV and gastritis, gastric cancer, and gastric ulcer: a two-sample Mendelian randomization study.Scientific reports · 2025Article
- Epstein-Barr virus infection promotes T cell dysregulation in a humanized mouse model of multiple sclerosis.Science advances · 2025Article
- Knowledge mapping of childhood infectious mononucleosis: a bibliometric analysis for the twenty-first century.Journal of health, population, and nutrition · 2025Article
- Double-stranded RNA antiviral signature in early multiple sclerosis.Frontiers in microbiology · 2025Article
- Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicators.Frontiers in immunology · 2025Article
- Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Connecting the Dots: Telomere Shortening and Rheumatic Diseases.Biomolecules · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 19 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS).
methodsSerum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany.
resultsEBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts.
conclusionThe complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.